PICOBOO Study

Can you help us learn more about the body’s immune response to COVID-19 vaccines?

The Platform Trial In COVID-19 Vaccine BOOsting (PICOBOO) Study is designed to evaluate the comparative effectiveness of COVID-19 booster vaccines.

Telethon Kids Institute researchers are working with study sites around Australia to see what effect COVID-19 booster vaccination has on the immune system, how long these effects last, and what the optimal booster strategies are for people living in Australia. The study will also explore the safety of booster vaccination and how well boosting protects against hospitalisation and disease.

Your participation in the PICOBOO Study will help researchers develop the most effective, long-term strategies for COVID-19 booster vaccinations nation-wide.

What does the study involve?

Participation in the PICOBOO Study will take place over a one-year period and involve five visits to the research clinic in Perth, Adelaide or Launceston. These appointments will include:

• randomised vaccination with one of the three approved COVID-19 booster vaccines
• providing blood and saliva samples to test for an individual's immune response before they receive their vaccine and at five additional time points over the study period
• completing regular SMS surveys

Are you eligible to participate?

Study researchers are urgently calling for the following participants:

• Adults 50 to 69 who have received Astra Zeneca or Pfizer as their primary dose and want to receive their 3rd booster (5th dose).
• Adults 70 and over who have received Astra Zeneca as their primary dose and want to receive their 3rd booster (5th dose).
• Adolescents aged 12 – 17 who have had two doses of Pfizer or two doses of Moderna and are interested in their 1st booster (3rd dose).

Please register for the PICOBOO Study here, or contact Vax4COVID@telethonkids.org.au

Adelaide residents can register their interest at VIRTU@adelaide.edu.au, and potential participants located in Launceston can email Research@cliffordcraig.org.au

This study has been approved by the Child and Adolescent Human Research Ethics Committee. Any person with concerns or complaints about the conduct of this study should contact the Executive Director Medical Services via [08 6456 2222] who can refer your concerns to the HREC monitoring the project.